Article Text

Download PDFPDF

Response to: ‘Anti-Ku antibodies: important points to consider’ by Mahler et al
  1. Mariko Ogawa-Momohara1,
  2. Yoshinao Muro2,
  3. Masashi Akiyama2
  1. 1 Nagoya Daigaku Daigakuin Igakukei Kenkyuka Igakubu, Nagoya, Japan
  2. 2 Dermatology, Nagoya University, Nagoya, Japan
  1. Correspondence to Dr Yoshinao Muro, Dermatology, Nagoya University, Nagoya, Japan; ymuro{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank the authors1 for their interest in our paper2 and are grateful for the opportunity to respond to the points raised. We agree with the opinion of Mahler et al that ‘SLE frequently express many autoantibodies and sera accompanied by mixed HEp-2 IIF pattern were very common’. We adopted the same methods for anti-Ku screening that Spielmann et al 3 used in their study to avoid missing multiple autoantibody-positive cases. The Spielmann group included ANA-positive sera showing several ANA patterns (ICAP nomenclature: AC-1, AC-4 or AC-5) for ELISA analysis.

Although Mahler et al noted that ‘In our experience, anti-Ku antibodies are frequently found in SLE patients potentially associated with overlap features of a myopathy’, of the four anti-Ku antibody-positive myositis patients in their referenced study, only two patients had systemic lupus erythematosus (SLE) overlapping with myositis.3 Given that 33 anti-Ku-positive SLE patients in their study4 did not have myositis, it seems that SLE and myositis are less likely to overlap. We need to be careful in discussing the frequency of anti-Ku-associated clinical phenotypes.

We detected anti-dsDNA and anti-ssDNA antibodies by using two commercial ELISA kits (MBL, Nagoya, Japan). These kits are commonly used in Japan and are covered by health insurance for clinical laboratory tests. As Mahler et al noted that there is variability between anti-dsDNA assays,1 we need to use immunofluorescence tests with Crithidia luciliae as a substrate for confirmation.

Ethics statements

Patient consent for publication



  • Handling editor Josef S Smolen

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles